Understand the source comparison
DSIP Research Review: Comparison of Study Methodologies
Early animal models (1977–1985) 1–50 μg/kg IV Intravenous (rabbit, rat) Delta-wave sleep percentage via EEG Short observation periods (6–12 hours); single-dose protocols Established proof-of-concept but didn't address chronic dosing or receptor mechanism Russi
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Early animal models (1977–1985)
- 1–50 μg/kg IV
- Intravenous (rabbit, rat)
- Delta-wave sleep percentage via EEG
- Short observation periods (6–12 hours); single-dose protocols
- Established proof-of-concept but didn't address chronic dosing or receptor mechanism
- Russian clinical trials (1985–1995)
- 0.5–5 mg IM/IV
- Intramuscular or intravenous
- Subjective sleep quality, polysomnography subset
- Small sample sizes (n=20–40); limited placebo controls; short duration (7–21 days)
- Showed statistically significant sleep architecture changes but lacked reproducibility in Western labs
- Western replication attempts (1990–2000)
- 10–50 μg IV
- Intravenous
- Sleep latency, REM/NREM distribution
- Failed to replicate Russian findings; inconsistent formulation purity
- Raised questions about formulation stability, injection timing, or population differences
- Pain/withdrawal studies (1986–1992)
- 0.5–1 mg IM
- Intramuscular
- Withdrawal symptom scores, pain VAS
- No follow-up beyond 21 days; confounded by concurrent medications
- Suggested adjunctive benefit but insufficient evidence for monotherapy efficacy
- Recent mechanistic studies (2005–2015)
- 10–100 μg/kg IP
- Intraperitoneal (rodent)
- HPA axis markers, GABA receptor binding
- Translational gap. Rodent findings don't predict human dosing
- Clarified possible GABAergic and opioid interactions but no human validation